Enlivex Therapeutics (US:ENLV) — Company Overview, News & Financial Data
Enlivex Therapeutics is a biotechnology firm developing immunotherapies for severe medical conditions like sepsis and COVID-19, aiming to innovate
About Enlivex Therapeutics
Enlivex Therapeutics (TASE:ENLV), (NASDAQ: ENLV) is a biotechnology company focused on developing novel therapies for severe medical conditions with unmet needs, including sepsis, COVID-19, and solid tumors. Its operations span from early-stage preclinical research to advanced clinical trials, aiming to harness the body's immune system to fight these critical conditions more effectively. Enlivex's projects include Allocetra™, an innovative immunotherapy designed to rebalance the immune system in life-threatening situations. The objective of Enlivex is to advance its pipeline of treatments through clinical development, striving to provide new solutions for patients facing diseases with limited treatment options.
Snapshot
Operations
Products and/or services of Enlivex Therapeutics
- Allocetra™, an immunotherapy for life-threatening conditions like sepsis and COVID-19 complications.
- Developing treatments for solid tumors through CAR-T and TCR platforms.
- Therapies targeting GvHD in bone marrow transplant patients.
- Research on prevention and treatment of acute kidney injury.
- Advancements in autoimmune disease therapies, focusing on rebalancing the immune system.
- Pipeline projects exploring novel approaches to organ transplant acceptance.
Enlivex Therapeutics executive team
- Mr. Shai Novik M.B.A.Executive Chairman
- Dr. Oren Hershkovitz Ph.D.Chief Executive Officer
- Prof. Dror Mevorach M.D.Founder & Scientific Advisor
- Ms. Shachar Shlosberger CPAChief Financial Officer
- Dr. Veronique Amor-BaroukhSenior Director of Operations
- Ms. Sigal AradDirector of Human Resources
- Dr. Einat Galamidi M.D.Chief Medical Officer